Core Viewpoint - Aidi Kang Holdings (09860) reported a mid-term performance for the six months ending June 30, 2025, with revenue of RMB 1.271 billion, a year-on-year decrease of 13.31% [1] Financial Performance - The company's total revenue reached RMB 1.271 billion, reflecting a decline of 13.3% year-on-year [1] - Profit attributable to equity holders of the parent company was RMB 27.273 million, down 73.15% year-on-year [1] - Earnings per share stood at RMB 0.04 [1] Business Segments - The co-construction business revenue grew by 30% year-on-year, with a four-year compound annual growth rate (CAGR) of 48%, primarily driven by successful projects with major tertiary hospitals [1] - The CRO (Contract Research Organization) business revenue increased by 18% year-on-year, supported by deep collaborations with leading domestic and international pharmaceutical companies [1] - The company maintained a strong position in the diabetes sector, achieved robust performance in the NASH (Non-Alcoholic Steatohepatitis) field, and made innovative breakthroughs in solid tumor treatment, expanding its business landscape [1] Future Outlook - The company plans to deepen strategic cooperation with leading medical institutions in the second half of the year to promote more benchmark projects [1]
艾迪康控股(09860)发布中期业绩，收益12.71亿元 共建业务收入同比增长30%